These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15333188)

  • 1. Evidence for the clinical use of tumour markers.
    Duffy MJ
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to integrate serum tumor markers into clinical oncologic practice.
    van Dalen A
    Nutrition; 1995; 11(5 Suppl):489-91. PubMed ID: 8748205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical usefulness of tumour markers.
    Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
    Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tumor markers in patients with breast cancer.
    Lumachi F; Basso SM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tumor markers in patients with solid cancers: A critical review.
    Duffy MJ
    Eur J Intern Med; 2007 May; 18(3):175-84. PubMed ID: 17449388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
    D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
    Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
    Margel D; Tal R; Baniel J
    J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tumour markers in clinical practice. Some general aspects.
    Kvinnsland S
    Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial designs for predictive marker validation in cancer treatment trials.
    Sargent DJ; Conley BA; Allegra C; Collette L
    J Clin Oncol; 2005 Mar; 23(9):2020-7. PubMed ID: 15774793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of tumour markers in cancer diagnosis and treatment.
    Higgins C
    Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours.
    Venkitaraman R; Johnson B; Huddart RA; Parker CC; Horwich A; Dearnaley DP
    BJU Int; 2007 Jul; 100(1):30-2. PubMed ID: 17552950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of plasma D-dimer levels in patients with colorectal cancer.
    Kilic M; Yoldas O; Keskek M; Ertan T; Tez M; Gocmen E; Koc M
    Colorectal Dis; 2008 Mar; 10(3):238-41. PubMed ID: 17868411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor markers in staging and prognosis of colorectal carcinoma.
    Levy M; Visokai V; Lipska L; Topolcan O
    Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.